Production (Stage)
Verrica Pharmaceuticals Inc.
VRCA
$0.6117
-$0.0083-1.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 899.71% | 119.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 899.71% | 119.31% | |||
| Cost of Revenue | -78.17% | 2,765.52% | |||
| Gross Profit | 105.92% | -446.98% | |||
| SG&A Expenses | -10.44% | -38.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.87% | -38.32% | |||
| Operating Income | 28.22% | 45.29% | |||
| Income Before Tax | 39.87% | 29.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 39.87% | 29.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.87% | 29.13% | |||
| EBIT | 28.22% | 45.29% | |||
| EBITDA | 28.21% | 45.56% | |||
| EPS Basic | 57.32% | 50.74% | |||
| Normalized Basic EPS | 57.09% | 51.00% | |||
| EPS Diluted | 57.32% | 50.74% | |||
| Normalized Diluted EPS | 57.09% | 51.00% | |||
| Average Basic Shares Outstanding | 40.86% | 43.84% | |||
| Average Diluted Shares Outstanding | 40.86% | 43.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||